Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 121 to 130 of 545 total matches.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
,
and a need for manual maneuvers to aid defecation.1
STANDARD TREATMENT — Dietary changes, fiber
supplements ...
The Vibrant orally administered vibrating capsule
(Vibrant Gastro), an FDA-cleared medical device, is
now available by prescription for treatment of adults
with chronic idiopathic constipation (CIC) who have
not experienced relief of their bowel symptoms
by using laxative therapies at the recommended
dosage for at least one month. It is the first drug-free
treatment to be authorized by the FDA for this
indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):65-7 doi:10.58347/tml.2023.1675a | Show Introduction Hide Introduction
Altuviiio – A Longer-Acting Factor VIII Product for Hemophilia A
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
of Altuviiio
was based on the results of two prospective, open-label
trials (XTEND-1 [published] and XTEND ...
The FDA has approved Altuviiio (Sanofi), a von
Willebrand Factor (VWF)-independent, recombinant
factor VIII concentrate, for routine prophylaxis, on-demand
treatment to control bleeding episodes, and
perioperative management of bleeding in children and
adults with hemophilia A. The manufacturer claims that
Altuviiio, which was previously called efanesoctocog
alfa, delivers normal to near-normal factor VIII levels for
most of the week with once-weekly intravenous dosing.
Med Lett Drugs Ther. 2023 May 1;65(1675):67-8 doi:10.58347/tml.2023.1675b | Show Introduction Hide Introduction
Lenacapavir (Sunlenca) for Multidrug-Resistant HIV
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
formulations of the HIV-1 capsid inhibitor lenacapavir
(Sunlenca – Gilead) for use with other antiretroviral ...
The FDA has approved oral and injectable
formulations of the HIV-1 capsid inhibitor lenacapavir
(Sunlenca – Gilead) for use with other antiretroviral
drugs to treat multidrug-resistant HIV-1 infection
(MDR-HIV) in heavily treatment-experienced adults
whose current regimen is failing. Lenacapavir is the
third drug to be approved exclusively for treatment
of MDR-HIV; the intravenously administered CD4-directed antibody ibalizumab-uiyk (Trogarzo) and the
orally administered HIV-1 gp120-directed attachment
inhibitor fostemsavir (Rukobia) were approved earlier.
Med Lett Drugs Ther. 2023 May 1;65(1675):68-70 doi:10.58347/tml.2023.1675c | Show Introduction Hide Introduction
Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
Verkazia (Santen), a 0.1%
ophthalmic emulsion formulation of the calcineurin
inhibitor cyclosporine ...
The FDA has approved Verkazia (Santen), a 0.1%
ophthalmic emulsion formulation of the calcineurin
inhibitor cyclosporine, for treatment of vernal
keratoconjunctivitis (VKC). Verkazia is the first
product to be approved in the US for this indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):70-2 doi:10.58347/tml.2023.1675d | Show Introduction Hide Introduction
In Brief: Over-the-Counter Narcan Nasal Spray
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
will be required to
switch them to OTC status and amend their labeling
accordingly.1 Kloxxado, an 8-mg naloxone ...
The FDA has approved the over-the-counter (OTC)
sale of Narcan (Emergent), a nasal spray that delivers
4 mg of the opioid antagonist naloxone. Narcan nasal
spray has been available by prescription since 2015
for emergency treatment of opioid overdose. Generic
formulations of Narcan have also been approved; the
manufacturers of these products will be required to
switch them to OTC status and amend their labeling
accordingly. Kloxxado, an 8-mg naloxone nasal
spray, remains available only by prescription.
Med Lett Drugs Ther. 2023 May 1;65(1675):72 doi:10.58347/tml.2023.1675e | Show Introduction Hide Introduction
Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
Not Previously Vaccinated
Previously Vaccinated with Monovalent Vaccine2
Previously Received ?1 Bivalent Dose3 ...
View the Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines
Med Lett Drugs Ther. 2023 May 1;65(1675):e1 doi:10.58347/tml.2023.1675f | Show Introduction Hide Introduction
COVID-19 Update: FDA Expands Bivalent Vaccine Use, Revises Vaccination Schedules
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 5063)
authorized for use in the US.1
All persons ≥6 months old who completed a primary
series with the Pfizer ...
The FDA has amended its Emergency Use Authorizations
(EUAs) for the bivalent mRNA COVID-19 vaccines
(original and Omicron BA.4/5 strains) manufactured by
Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax)
to permit their use for all doses administered to persons
≥6 months old. The monovalent Pfizer and Moderna
vaccines are no longer authorized for use in the US
Med Lett Drugs Ther. 2023 May 1;65(5063):1 doi:10.58347/tml.2023.5063a | Show Introduction Hide Introduction
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
– Esperion) in 2020,1
cardiovascular outcomes data in statin-intolerant
patients have become available ...
Since our initial review of the oral lipid-lowering
adenosine triphosphate-citrate lyase (ACL) inhibitor
bempedoic acid (Nexletol – Esperion) in 2020,
cardiovascular outcomes data in statin-intolerant
patients have become available.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):62-3 doi:10.58347/tml.2023.1674b | Show Introduction Hide Introduction